Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from http://www.ncbi.nlm.nih.gov/pubmed/32522832 below:

Medical Care Costs Associated with Cancer Survivorship in the United States

Affiliations

• ¹ Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland. mariotta@mail.nih.gov.
• ² Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland.
• ³ Surveillance and Health Services Research, American Cancer Society, Atlanta, Georgia.
• ⁴ Information Management Services, Inc., Calverton, Maryland.

• PMID: 32522832
• PMCID: PMC9514601
• DOI: 10.1158/1055-9965.EPI-19-1534

Item in Clipboard

Angela B Mariotto et al. Cancer Epidemiol Biomarkers Prev. 2020 Jul.

• ¹ Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland. mariotta@mail.nih.gov.
• ² Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland.
• ³ Surveillance and Health Services Research, American Cancer Society, Atlanta, Georgia.
• ⁴ Information Management Services, Inc., Calverton, Maryland.

• PMID: 32522832
• PMCID: PMC9514601
• DOI: 10.1158/1055-9965.EPI-19-1534

Item in Clipboard

Background: The prevalence of cancer survivorship is increasing. In this study, we provide contemporary population-based estimates and projections of the overall and site-specific cancer-attributable medical care costs in the United States.

Methods: We identified survivors aged ≥65 years diagnosed with cancer between 2000 and 2012 from the Surveillance, Epidemiology, and End Results (SEER)-Medicare database and used 2007 to 2013 claims to estimate costs by cancer site, phases of care, and stage at diagnosis. Annualized average cancer-attributable costs for medical care (Medicare Parts A and B) and oral prescription drugs (Medicare Part D) were estimated by subtracting costs between patients with cancer and matched controls. Costs are reported in 2019 U.S. dollars. We combined phase-specific attributable costs with prevalence projections to estimate national costs from 2015 through 2030.

Results: Overall annualized average costs were highest in the end-of-life-cancer death phase, followed by the initial and continuing phases (medical care: $105,500, $41,800, and $5,300 and oral prescription drugs: $4,200, $1,800, $1,100, respectively). There was considerable variation in costs by cancer site and stage. Overall national costs in 2015 were $183 billion and projected to increase 34% to $246 billion by 2030, based only on population growth.

Conclusions: Phase of care cancer-attributable cost estimates by cancer site and stage are key inputs for simulation models and cost-effectiveness analyses.

Impact: The national cancer-attributed medical care costs in the United States are substantial and projected to increase dramatically by 2030, due to population changes alone, reflecting the rising burden of cancer care among cancer survivors.

©2020 American Association for Cancer Research.

PubMed Disclaimer

The authors declare no potential conflicts of interest.

• Projections of the cost of cancer care in the United States: 2010-2020.

  Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Mariotto AB, et al. J Natl Cancer Inst. 2011 Jan 19;103(2):117-28. doi: 10.1093/jnci/djq495. Epub 2011 Jan 12. J Natl Cancer Inst. 2011. PMID: 21228314 Free PMC article.

• Cost of care for elderly cancer patients in the United States.

  Yabroff KR, Lamont EB, Mariotto A, Warren JL, Topor M, Meekins A, Brown ML. Yabroff KR, et al. J Natl Cancer Inst. 2008 May 7;100(9):630-41. doi: 10.1093/jnci/djn103. Epub 2008 Apr 29. J Natl Cancer Inst. 2008. PMID: 18445825

• Annual Report to the Nation on the Status of Cancer, Part 2: Patient Economic Burden Associated With Cancer Care.

  Yabroff KR, Mariotto A, Tangka F, Zhao J, Islami F, Sung H, Sherman RL, Henley SJ, Jemal A, Ward EM. Yabroff KR, et al. J Natl Cancer Inst. 2021 Nov 29;113(12):1670-1682. doi: 10.1093/jnci/djab192. J Natl Cancer Inst. 2021. PMID: 34698839 Free PMC article.

• Economic costs of diabetes in the U.S. In 2007.

  American Diabetes Association. American Diabetes Association. Diabetes Care. 2008 Mar;31(3):596-615. doi: 10.2337/dc08-9017. Diabetes Care. 2008. PMID: 18308683 Review.

• Current estimates of the economic cost of obesity in the United States.

  Wolf AM, Colditz GA. Wolf AM, et al. Obes Res. 1998 Mar;6(2):97-106. doi: 10.1002/j.1550-8528.1998.tb00322.x. Obes Res. 1998. PMID: 9545015 Review.

• The incremental healthcare cost associated with cancer in Belgium: A registry-based data analysis.

  Gorasso V, Vandevijvere S, Van der Heyden J, Pelgrims I, Hilderink H, Nusselder W, Demoury C, Schmidt M, Vansteelandt S, De Smedt D, Devleesschauwer B. Gorasso V, et al. Cancer Med. 2024 Feb;13(3):e6659. doi: 10.1002/cam4.6659. Epub 2024 Jan 24. Cancer Med. 2024. PMID: 38268318 Free PMC article.

• Prostate cancer aggressiveness and financial toxicity among prostate cancer patients.

  Kc M, Oral E, Rung AL, Trapido E, Rozek LS, Fontham ETH, Bensen JT, Farnan L, Steck SE, Song L, Mohler JL, Khan S, Vohra S, Peters ES. Kc M, et al. Prostate. 2023 Jan;83(1):44-55. doi: 10.1002/pros.24434. Epub 2022 Sep 5. Prostate. 2023. PMID: 36063402 Free PMC article.

• Comparative cost savings of biosimilar and dose rounding utilization in oncology care.

  Abdelmeseh V, Brown BR, Huynh JP, Zullo AR. Abdelmeseh V, et al. J Oncol Pharm Pract. 2023 Sep;29(6):1437-1442. doi: 10.1177/10781552221134257. Epub 2022 Oct 19. J Oncol Pharm Pract. 2023. PMID: 36259235 Free PMC article.

• Prevalence of lung cancer in Colombia and a new diagnostic algorithm using health administrative databases: A real-world evidence study.

  Amaya-Nieto J, Torres G, Buitrago G. Amaya-Nieto J, et al. PLoS One. 2023 Mar 10;18(3):e0269079. doi: 10.1371/journal.pone.0269079. eCollection 2023. PLoS One. 2023. PMID: 36897924 Free PMC article.

• Digital Health Applications in Oncology: An Opportunity to Seize.

  Parikh RB, Basen-Enquist KM, Bradley C, Estrin D, Levy M, Lichtenfeld JL, Malin B, McGraw D, Meropol NJ, Oyer RA, Sheldon LK, Shulman LN. Parikh RB, et al. J Natl Cancer Inst. 2022 Oct 6;114(10):1338-1339. doi: 10.1093/jnci/djac108. J Natl Cancer Inst. 2022. PMID: 35640986 Free PMC article.

1. 1. Bluethmann SM, Mariotto AB, Rowland JH. Anticipating the “Silver Tsunami”: Prevalence Trajectories and Comorbidity Burden among Older Cancer Survivors in the United States. Cancer Epidemiol Biomarkers Prev. 2016;25(7):1029–36. - PMC - PubMed
2. 1. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst. 2011;103(2):117–28. - PMC - PubMed
3. 1. Bradley CJ, Yabroff KR, Mariotto AB, Zeruto C, Tran Q, Warren JL. Antineoplastic Treatment of Advanced-Stage Non-Small-Cell Lung Cancer: Treatment, Survival, and Spending (2000 to 2011). J Clin Oncol. 2017;35(5):529–35. - PMC - PubMed
4. 1. Bradley CJ, Yabroff KR, Warren JL, Zeruto C, Chawla N, Lamont EB. Trends in the Treatment of Metastatic Colon and Rectal Cancer in Elderly Patients. Med Care. 2016;54(5):490–7. - PubMed
5. 1. Bach PB. Limits on Medicare’s ability to control rising spending on cancer drugs. N Engl J Med. 2009;360(6):626–33. - PubMed

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3